Document Server@UHasselt >
Research publications >
Please use this identifier to cite or link to this item:
|Title: ||Mono- and bispecific single-chain antibody fragments for cancer therapy|
|Authors: ||Thirion, S|
|Issue Date: ||1996|
|Publisher: ||RAPID SCIENCE PUBLISHERS|
|Citation: ||EUROPEAN JOURNAL OF CANCER PREVENTION, 5(6). p. 507-511|
|Abstract: ||Especially when dealing,vith solid cancers, single-chain antibody fragments (scFvs) have a lot of advantages. Due to their small size (27 kDa), these proteins clear more rapidly from the blood, and penetrate faster and deeper into tissues, than whole antibodies. Furthermore, the lack of constant regions ensures that they are not retained in tissues such as the liver and kidney. This reduces possible toxic side-effects. Single-chain construction is normally done by polymerase chain reaction (PCR). To decrease the overall cost of oligonucleotide primer synthesis, time-consuming primer design, multiple PCR reactions and individual PCR optimization, we designed a universal single-step overlap extension PCR protocol using hybridoma cDNA as a template. To overcome the lack of effector function, bispecific scFvs, consisting of an scFv produced against a tumour-associated antigen fused to a T cell marker-specific scFv, are being created, starting from already assembled scFv, by means of two additional PCR reactions. In this paper we describe both PCR methods that were successfully used to create scFvs against the human transferrin receptor, the human interleukin-3 receptor, the human CD3 molecule, a breast tumour-associated antigen and an anti-transferrin-anti-CD3 bispecific scFv.|
|Notes: ||LIMBURGS UNIV CTR,B-3590 DIEPENBEEK,BELGIUM.Thirion, S, DR WILLEMS INST,DEPT BIOTECHNOL,UNIV CAMPUS,GEBOUW A,B-3590 DIEPENBEEK,BELGIUM.|
|ISI #: ||A1996WL97600014|
|Type: ||Journal Contribution|
|Appears in Collections: ||Research publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.